• Mashup Score: 0
    Allopurinol Does Not Improve Cardiovascular Outcomes in Ischaemic Heart Disease Patients - 2 year(s) ago

    September 1, 2022 — The gout medicine allopurinol has failed to reduce the primary endpoint of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death in patients with ischaemic heart disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2022. Allopurinol is a xanthine oxidase inhibitor that lowers uric acid and is used to treat…

    Source: DAIC
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DAICeditor
      DAICeditor

      @DAICeditor @escardio #Gout medicine #allopurinol failed to reduce the primary endpoint of nonfatal #myocardialinfarction, nonfatal #stroke or #cardiovasculardeath in patients with #ischaemic #heartdisease, according to #ESCCongress: https://t.co/V9Sz8ET1Tz #esc2022

  • Mashup Score: 1
    Allopurinol fails to improve outcomes in ischemic heart disease - 2 year(s) ago

    In patients with ischemic heart disease older than 60 years, the anti-inflammatory drug allopurinol did not improve CV outcomes, according to results of the ALL-HEART trial presented at the European Society of Cardiology Congress. Isla Mackenzie, MBChB (Hon), PhD, FRCP Edin, FBPharmacolS, professor of cardiovascular medicine and honorary consultant physician at University of Dundee and

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      In patients with ischemic heart disease older than 60 years, the anti-inflammatory drug #allopurinol did not improve CV outcomes, according to results of the ALL-HEART trial @dundeeuni @HealioRheum @ESCardioNews #ESCCongress #CardioTwitter https://t.co/pqOBfmjeme

  • Mashup Score: 2
    Why Do Patients With Gout Not Take Allopurinol? - 2 year(s) ago

    Objective. The objectives of this study were to examine the reasons patients give for nonadherence to allopurinol and to examine differences in intentional nonadherence for patients who did and did not achieve serum urate (SU) levels at treatment target. Methods. Sixty-nine men with gout attending rheumatology clinics, all prescribed allopurinol for ≥ 6 months, completed the Intentional…

    Source: The Journal of Rheumatology
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of jrheum
      jrheum

      Editor's Picks Spotlight Why Do Patients With Gout Not Take Allopurinol? @KeithPetrie @YasamanEmad #gout #allopurinol #rheumatology #medtwitter Read the full article 📰 https://t.co/hu5w6mperI Watch the video 📺 https://t.co/4sSq6YZDU5

  • Mashup Score: 1
    Annals of Internal Medicine - 2 year(s) ago

    Original ResearchReviewsClinical GuidelinesEditorialsLettersRace/Ethnicity Trends Among U.S. Internal Medicine Residency Applicants and Matriculants: A Cross-Sectional StudyWeb ExclusivesOriginal ResearchReviewsClinical GuidelinesHistory of MedicineEditorialsOn Being a PatientWeb ExclusivesOriginal ResearchEditorialsLettersAntibody Response to a Fourth Messenger RNA COVID-19…

    Source: Annals of Internal Medicine
    Categories: General Medicine Journals and Societies, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AnnalsofIM
      AnnalsofIM

      This week’s issue of Annals of Internal Medicine is online now. Check out new practice points on #COVID19 antibody response, #allopurinol treatment for #gout and #CKD, and more: https://t.co/qbqAvauqci

  • Mashup Score: 0
    ‘Treat-to-target is key’: Allopurinol noninferior to febuxostat for gout when properly dosed - 2 year(s) ago

    Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy, according to data presented at ACR Convergence 2021.The data emphasize the significance of following the American College of Rheumatology or EULAR treatment recommendations, as opposed to guidelines from the American College of Physicians, which “does not recognize” the

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      ‘#TreatToTarget is key’: #Allopurinol is noninferior to #febuxostat for #gout when properly dosed according to data presented at #ACR21 https://t.co/ACswDMZIJQ https://t.co/MBhvjmIEmt

  • Mashup Score: 5
    ‘Treat-to-target is key’: Allopurinol noninferior to febuxostat for gout when properly dosed - 2 year(s) ago

    Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy, according to data presented at ACR Convergence 2021.The data emphasize the significance of following the American College of Rheumatology or EULAR treatment recommendations, as opposed to guidelines from the American College of Physicians, which “does not recognize” the

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      When dosed as part of a #TreatToTarget strategy, #allopurinol was found to be noninferior to #febuxostat for #gout according to data presented at #ACR21 by @unmc researchers https://t.co/ACswDMZIJQ

  • Mashup Score: 0
    'Influx of newer agents' in gout pipeline hold promise for shifting treatment paradigm - 3 year(s) ago

    Although allopurinol, febuxostat and pegloticase are still relied on to do the heavy lifting in lowering urate for patients with gout, an “influx of newer agents” may help expand effective disease management, according to a presenter here.“In the 21st century, we often think that RA is the most common condition — why? Because we have so many different medications available

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      #Allopurinol and #pegloticase are still needed to do the heavy lifting in lowering #urate for #gout patients, but new agents in the #DrugPipeline - like #anakinra #verinurad and #arhalofenate - could expand the treatment toolbox #CCR21 #CCREast21 https://t.co/fsOQ7sNnjM

Load More